- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02204501
A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers
A Phase 1, Randomized, Open-Label Study to Evaluate the Effect of Vapendavir (BTA798) on the Pharmacokinetics of Orally Administered Midazolam, a CYP3A4 Substrate, in Healthy Male and Female Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55114
- Prism Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be male or female between 18 and 55 years of age (inclusive) with BMI between 18 and 30 kg/m2 (inclusive), and weight ≥50 kg at the time of screening;
- Capable of giving written informed consent;
- Subject is able to understand and comply with the protocol requirements, instructions and restrictions;
- Healthy on the basis of physical examination, medical history, medication usage, vital signs (VS), electrocardiograms (ECGs), and clinical laboratory tests;
- Female subjects who are not post-menopausal for at least 2 years or surgically sterile with complete hysterectomy or bilateral oophorectomy and male subjects who are not surgically sterile via vasectomy, must agree to use a double barrier method of birth control, such as a condom plus spermicidal agent (foam/gel/film/cream/suppository); and
- Female subjects must not be breastfeeding or pregnant.
Exclusion Criteria:
- Positive results for Hepatitis B, Hepatitis C, or HIV;
- Frequent use (defined as > 5 times/day) of tobacco products, including cigarettes, cigars, chewing tobacco;
- A medical history of significant hematological, gastrointestinal, respiratory, renal, hepatic, cerebrovascular, immunologic, psychiatric or cardiovascular disease or event;
- Current or recent respiratory infection (defined as within 14 days of first study visit participation)
- Presence or history of significant allergy;
- Clinically significant abnormalities noted on ECG;
- Screening vital signs representing sustained elevated systolic blood pressure <90 mmHg or >140 mmHg, and/or diastolic blood pressure <55 mmHg or >90 mmHg.
- Presence of significant gastrointestinal abnormalities such as diarrhea or constipation;
- Safety laboratory abnormalities noted at screening which are clinically significant
- Current or defined history of abuse of alcohol or illicit drugs;
- A positive pregnancy test at screening;
- Poor vein access or fear of venipuncture or sight of blood; and
- Regular consumption of alcohol defined as either > 2 units (glass or shot) of alcoholic beverages per day or > 14 units per week.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vapendavir 528 mg QD
Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
|
All twenty four subjects will receive 5 mg midazolam syrup at four different time points during the study for a total of four non-subsequent dosing days.
Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
|
Experimental: Vapendavir 264 mg BID
Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
|
All twenty four subjects will receive 5 mg midazolam syrup at four different time points during the study for a total of four non-subsequent dosing days.
Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Effect of Vapendavir on the PK Profile of Midazolam
Time Frame: End of Study (up to 46 weeks in duration)
|
To evaluate the effect of vapendavir daily dose of 264 mg BID on the PK profile of midazolam, a CYP3A4 substrate. The primary outcome will be evaluated through a series of analyses of PK parameters including:
|
End of Study (up to 46 weeks in duration)
|
The Effect of Vapendavir on the PK Profile of Midazolam
Time Frame: End of Study (up to 46 weeks in duration)
|
To evaluate the effect of vapendavir daily dose of 528 mg QD on the PK profile of midazolam, a CYP3A4 substrate. The primary outcome will be evaluated through a series of analyses of PK parameters including:
|
End of Study (up to 46 weeks in duration)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess Whether PK Profile of Vapendavir is Affected by Presence of Midazolam
Time Frame: End of Study (up to 46 weeks in duration)
|
To evaluate whether the PK profile of vapendavir, is affected by the presence of midazolam, a strong CYP3A4 substrate. This outcome will be evaluated through a series of analyses of PK parameters for vapendavir including:
|
End of Study (up to 46 weeks in duration)
|
Assess the Safety of Vapendavir
Time Frame: End of Study (up to 46 weeks in duration
|
To evaluate the safety of vapendavir.
This will be accomplished by assessing adverse events, clinical laboratory tests (including blood chemistry, hematology with differential and urinalysis), physical exams, ECG assessments, vital sign assessments and concomitant medications.
|
End of Study (up to 46 weeks in duration
|
Collaborators and Investigators
Investigators
- Principal Investigator: Mark Matson, MD, Prism Clinical Research
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Midazolam
Other Study ID Numbers
- BTA798-102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug-Drug Interaction Healthy Volunteers
-
University of Southern DenmarkSignaTope GmbH, GermanyCompleted
-
University of WashingtonNational Institute of General Medical Sciences (NIGMS)CompletedHealthy Volunteers | Drug-Drug Interaction
-
University of Southern DenmarkCompletedHealthy Volunteers | Drug-drug InteractionDenmark
-
Central South UniversityCompletedDrug Interaction of Olmesartan in Healthy Chinese VolunteersChina
-
Idorsia Pharmaceuticals Ltd.CompletedHealthy | Drug Drug InteractionCzechia
-
JemincareCompleted
-
KBP BiosciencesCovanceCompletedHealthy | Drug Drug InteractionUnited States
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHealthy Subjects, Drug-drug Interaction, PyrotinibChina
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedHealthy Subjects | Pharmacokinetics | Drug-Drug InteractionFrance
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Drug-Drug Interaction (DDI)United Kingdom
Clinical Trials on Midazolam 5mg Syrup
-
Chulalongkorn UniversityUnknown
-
Penn State UniversityZarbee's Inc.Completed
-
Routin SACompletedHealthy VolunteersFrance
-
Jessica RiguttoUniversity of Oxford; Jomo Kenyatta University of Agriculture and Technology... and other collaboratorsCompletedIron-deficiency | Iron Deficiency Anemia | Pediatric ALL | VaccinationKenya, Switzerland
-
VIST - Faculty of Applied SciencesEuropean Regional Development Fund; Slovenian Research Agency; Valens Int. d.o... and other collaboratorsCompletedDermis Density | Minimal Erythema Dose | Skin ViscoelasticitySlovenia
-
Shifa Ul Mulk Memorial HospitalRecruiting
-
Laval UniversityCompletedOverweight | Metabolic Syndrome | Insulin Resistance | Endotoxemia | Non-Alcoholic Fatty Liver Disease | MicrobiotaCanada
-
University of British ColumbiaCompletedFocus of Study: Oral Tolerance Test With Glucose, Lactose, SucroseCanada
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...UnknownPatient ComplianceBangladesh
-
Boston Children's HospitalNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedAcute Otitis MediaUnited States